

Shield Therapeutics plc
("Shield" or the "Company" or the "Group")

Block Listing 6 Monthly Return

Name of applicant:	SHIELD THERAPEUTICS PLC		
Name of scheme:	Shield Therapeutics Retention Share Plan		
Period of return:	From:	30 September 2022	To: 31 March 2023
Balance of unallotted securities under scheme(s) from previous return:	39,794		
<u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	NIL		
<u>Less:</u> Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	NIL		
<u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period:	39,794		

Name of applicant:	SHIELD THERAPEUTICS PLC		
Name of scheme:	Shield Therapeutics plc 2016 Company Share Option Plan		
Period of return:	From:	30 September 2022	To: 31 March 2023
Balance of unallotted securities under scheme(s) from previous return:	341,020		
<u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	NIL		
<u>Less:</u> Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	NIL		
<u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period:	341,020		

Name of applicant:	SHIELD THERAPEUTICS PLC		
Name of scheme:	The Shield Therapeutics plc 2016 Long Term Incentive Plan		
Period of return:	From:	30 September 2022	To: 31 March 2023
Balance of unallotted securities under scheme(s) from previous return:	24,273		
<u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	NIL		
<u>Less:</u> Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	NIL		
<u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period:	24,273		

Name of applicant:	SHIELD THERAPEUTICS PLC		
Name of scheme:	Shield Therapeutics Retention and Performance Share Plan		
Period of return:	From:	30 September 2022	To: 31 March 2023
Balance of unallotted securities under scheme(s) from previous return:	4,870,838		
<u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	NIL		
<u>Less:</u> Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	2,000,000		
<u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period:	2,870,838		

Name of contact:	Lucy Huntington-Bailey		
Telephone number of contact:	+44 (0) 191 511 8500		

For further information please contact:

Shield Therapeutics plc
Greg Madison, CEO
Hans-Peter Rudolf, CFO

www.shieldtherapeutics.com
+44 (0) 191 511 8500

Nominated Adviser and Joint Broker

Peel Hunt LLP

James Steel/Oliver Duckworth

+44 (0)20 7418 8900

Joint Broker

finnCap Ltd

Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks

+44 (0)20 7220 0500

Financial PR & IR Advisor

Walbrook PR

Lianne Applegarth/Alice Woodings

+44 (0)20 7933 8780 or shield@walbrookpr.com

Investor Contact (US Advisor)

LifeSci Advisors, LLC

John Mullaly

+1 617 429 3548 or jmullaly@lifesciadvisors.com

About Accrufer®/Feraccru®

Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of action compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

Accrufer®/Feraccru® has patent coverage until the mid-2030s

Accrufer®/Feraccru® are registered trademarks of the Shield Group

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BLREAXDEDFKDEFA